Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
AbbVie is successfully navigating the Humira patent cliff by driving strong growth in its newer immunology assets, Skyrizi and Rinvoq. The company remains a highly cash-generative powerhouse capable of supporting a robust and growing dividend.
A severe margin contraction driven by pricing reform and aggressive biosimilar uptake stresses FCFFree cash flowOperating cash flow minus capital expenditures. The cash a business generates after maintaining and growing its asset base — the closest accounting proxy for owner-economics.. Debt load from Allergan acquisition amplifies equity risk, constraining dividend growth and leading to a structural multiple de-rating.
Biosimilar competition erodes Humira revenues significantly faster than projected, compressing margins.
Key immunology assets fail to reach peak sales targets or face unexpected safety concerns.
Aggressive legislative action structurally reduces pricing power across the pharmaceutical portfolio.
| Concepto | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
|---|---|---|---|---|---|
| Ingresos | $58.05B | $54.32B-6.4% | $56.33B+3.7% | $61.16B+8.6% | +1.8% |
| Beneficio bruto | $40.64B | $33.90B | $39.43B | $42.96B | +1.9% |
| Beneficio operativo | $18.81B | $13.54B | $11.89B | $20.09B | +2.2% |
| Beneficio neto | $11.84B | $4.86B-59.0% | $4.28B-11.9% | $4.23B-1.2% | -29.1% |
| BPA (diluido) | $6.63 | $2.72 | $2.39 | $2.36 | -29.1% |
| EBITDA | $24.17B | $17.17B | $14.91B | $17.63B | -10.0% |
| I+D | $6.51B | $7.68B | $12.79B | $9.10B | +11.8% |
| SG&A | $15.26B | $12.87B | $14.75B | $14.01B | -2.8% |
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
